SandboxAQ launched AQBioSim, a dedicated division that combines artificial intelligence with physics- and quantum-informed molecular simulation to speed up drug discovery, following several years of development that had stayed out of public view. The division is working with AstraZeneca, Sanofi, and UCSF on treatments for cancer, Alzheimer's, and Parkinson's disease, using simulation to model how a drug candidate will behave before it ever reaches a lab bench. Physician and author Siddhartha Mukherjee said the approach gives SandboxAQ an unusual ability to deliver first-in-class molecules. SandboxAQ is a Parkway Venture Capital portfolio company.
Read the full article: SandboxAQ's announcement of its AQBioSim division
Share
Greatness lies ahead
Sign up for updates from the cutting edge of deep tech venture capital.
You’re on the list!
Something went wrong while submitting the form.
